Published ahead of print on April 25, 2008, doi:10.1165/rcmb.2007-0024OC Am. J. Respir. Cell Mol. Biol., Volume 39, Number 4, October 2008, 420-430 A more recent version of this article appeared on October 1, 2008
Submitted on January 26, 2007 Developmental Regulation of NO-mediated VEGF-induced Effects in the LungVineet Bhandari1*,1 Department of Pediatrics, Yale University School of Medicine, Division of Perinatal Medicine, New Haven, CT, USA, 2 Department of Internal Medicine, Yale University School of Medicine, Section of Pulmonary and Critical Care Medicine, New Haven, CT, USA, 3 Department of Pediatrics, University of Alabama School of Medicine, Division of Neonatology, Birmingham, AL, USA, 4 Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA, 5 Department of Pathology, Yale University School of Medicine, New Haven, CT, USA * To whom correspondence should be addressed. E-mail: vineet.bhandari{at}yale.edu.
Background: VEGF is known to have a pivotal role in lung development and in a variety of pathological conditions in the adult lung. Our earlier studies have shown that NO is a critical mediator of VEGF-induced vascular and extra-vascular effects in the adult murine lung. Since significant differences have been reported in the cytokine responses in the adult versus the neonatal lung, we hypothesized that there may be significant differences in VEGF-induced alterations in the developing as opposed to the mature lung. Furthermore, NO-mediation of these VEGF-induced effects may be developmentally regulated. Methods and Results: Using a novel externally-regulatable lung-targeted transgenic murine model, we found that VEGF induced pulmonary hemorrhage was mediated by NO-dependent mechanisms in adults and newborns. VEGF enhanced surfactant production in adults as well as increased surfactant and lung development in newborns, via a NO-independent mechanism. While the enhanced survival in hyperoxia in the adult was partly NO-dependent, there was enhanced hyperoxia-induced lung injury in the newborn. In addition, human amniotic fluid VEGF levels correlated positively with surfactant phospholipids. Tracheal aspirate VEGF levels had an initial spike, followed by a decline, and then a subsequent rise, in human neonates with an outcome of bronchopulmonary dysplasia or death. Conclusions: Our data shows that VEGF can have injurious as well as potentially beneficial developmental effects, of which some are NO-dependent, others NO-independent. This opens up the possibility of selective manipulation of any VEGF-based intervention using NO-inhibitors for maximal potential clinical benefit.
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||